DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1671)

Systemic Lupus Erythematosus | Landscape & Forecast | Disease Landscape & Forecast

Systemic Lupus Erythematosus | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

SLE is an autoimmune condition characterized by varied symptoms and multiple organ involvement, making it a complex disease, which is difficult to manage. Moreover, challenges in clinical trial design and in understanding potential market for SLE therapies often impede drug development, leading to high failure rates of pipeline agents. To date, Benlysta is the only approved biologic for SLE, which caters to a specific SLE population, leaving high unmet need in the SLE space. Pharmaceutical companies have identified the hidden commercial opportunity in this area and, currently, SLE pipeline has several agents in late-phase and many more in early-phase development. The SLE Disease Landscape and Forecast offers detailed insights into current medical practices, key unmet needs, and new developments in SLE space, along with an analysis of opportunities and obstacles faced by emerging agents.

Questions Answered:

  • How large is the drug-treated SLE population, and how is it going to emerge during the 2016-2026 forecast period?
  • How large is the treatable SLE population and how will diagnosis/drug-treatment rates change over time?
  • What is the current state of treatment in SLE? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What are the key unmet needs in SLE?
  • Which novel therapies are most promising, and what sales/uptake could they secure in SLE? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the SLE market, and how will the market evolve over the forecast period?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: Approximately 30 country-specific interviews with rheumatologists and nephrologists.

Epidemiology: Diagnosed prevalence of SLE by country and subpopulations (nonrenal SLE and lupus nephritis).

Population segments in market forecast: Total population, nonrenal SLE population, renal SLE (LN) population.

Emerging therapies: Phase II: 20 drugs; Phase III: 6 drugs; Coverage of 7 select preclinical and Phase I products.

  • Pub Date: June 2018
  • Author(s): Mohit Nasa, MBA

Purchase Report

Recent reports:
You may also be interested in: